Trillium Therapeutics Company Profile (TSE:SSS)

About Trillium Therapeutics (TSE:SSS)

Trillium Therapeutics logoTrillium Therapeutics Inc is a Canada-based clinical stage immuno-oncology company developing therapies for the treatment of cancer. Its SIRPaFc (TTI-621) program, which is under Phase I clinical trial, is a fusion protein that consists of the CD47-binding domain of human SIRPa linked to the fragment crystallizable (Fc) region of a human immunoglobulin (IgG1). It acts as a soluble decoy receptor, preventing CD47 from delivering its inhibitory signal. Neutralization of the inhibitory CD47 signal enables the activation of macrophage anti-tumor effects by pro-phagocytic signals. It also has a medicinal chemistry platform, which permits the creation of new chemical entities from validated drugs and drug candidates with managed pharmacological properties. Its preclinical program is an orally-available bromodomain inhibitor, followed by an epidermal growth factor receptor antagonist with increased uptake in the brain. In addition, a number of compounds are in the discovery phase.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Symbol: TSE:SSS
  • CUSIP: N/A
  • Web: N/A
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0.00

Frequently Asked Questions for Trillium Therapeutics (TSE:SSS)

What is Trillium Therapeutics' stock symbol?

Trillium Therapeutics trades on the Tornton Stock Exchange (TSX) under the ticker symbol "SSS."

Who are some of Trillium Therapeutics' key competitors?

How do I buy Trillium Therapeutics stock?

Shares of Trillium Therapeutics and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

Analyst Ratings

Consensus Ratings for Trillium Therapeutics (TSE:SSS) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Trillium Therapeutics (TSE:SSS)
No equities research coverage for this company has been tracked by


Earnings History for Trillium Therapeutics (TSE:SSS)
No earnings announcements for this company have been tracked by


Earnings Estimates for Trillium Therapeutics (TSE:SSS)

No earnings estimates for this company have been tracked by


Dividend History for Trillium Therapeutics (TSE:SSS)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Trillium Therapeutics (TSE:SSS)
Insider Trades by Quarter for Trillium Therapeutics (TSE:SSS)
Insider Trades by Quarter for Trillium Therapeutics (TSE:SSS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/2/2017Michael Bruno John Fr EnglandDirectorBuy100,000C$0.15C$15,000.00
4/20/2017Michael Bruno John Fr EnglandDirectorBuy11,500C$0.12C$1,380.00
4/19/2017Michael Bruno John Fr EnglandDirectorBuy50,000C$0.12C$6,000.00
4/13/2017Donald Laughlin MckinnonDirectorBuy20,000C$0.13C$2,600.00
4/10/2017Michael Bruno John Fr EnglandDirectorBuy12,000C$0.10C$1,200.00
3/27/2017Michael Bruno John Fr EnglandDirectorBuy5,000C$0.19C$950.00
3/22/2017Gordon Edward ZelkoDirectorBuy20,000C$0.10C$2,000.00
2/17/2017Michael Bruno John Fr EnglandDirectorBuy50,000C$0.12C$6,000.00
2/7/2017Gordon Edward ZelkoDirectorBuy50,000C$0.11C$5,500.00
1/31/2017Michael Bruno John Fr EnglandDirectorBuy20,000C$0.11C$2,200.00
(Data available from 1/1/2013 forward)


Headline Trends for Trillium Therapeutics (TSE:SSS)
Latest Headlines for Trillium Therapeutics (TSE:SSS)



Trillium Therapeutics (SSS) Chart for Sunday, May, 28, 2017

This page was last updated on 5/28/2017 by Staff